Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells

The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2015/09/01, Vol.38(9), pp.1410-1414
Main Authors: Kuwahara, Jun, Yamada, Takaaki, Egashira, Nobuaki, Ueda, Mitsuyo, Zukeyama, Nina, Ushio, Soichiro, Masuda, Satohiro
Format: Article
Language:English
Subjects:
anti-tumor effect
Antineoplastic Agents - pharmacology
Carcinoma, Hepatocellular
Caspase 3 - metabolism
Caspase 7 - metabolism
Cell Line, Tumor
Cell Survival - drug effects
Citalopram - pharmacology
Cyclopropanes - pharmacology
Duloxetine Hydrochloride - pharmacology
Fluvoxamine - pharmacology
Hep G2 Cells
human hepatocellular carcinoma cell
Humans
Liver Neoplasms
Paroxetine - pharmacology
selective serotonin reuptake inhibitor
Serotonin and Noradrenaline Reuptake Inhibitors - pharmacology
serotonin and norepinephrine reuptake inhibitor
Serotonin Uptake Inhibitors - pharmacology
sertraline
Sertraline - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 µM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.b15-00128